Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

This study has been completed.
Samsung Medical Center
Information provided by (Responsible Party):
SillaJen, Inc. ( Jennerex Biotherapeutics ) Identifier:
First received: June 22, 2011
Last updated: January 6, 2016
Last verified: March 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)